source
- Iambic Therapeutics eyes IPO as it pushes HER2 inhibitor IAM1363 into early trialsIambic Therapeutics, a San Diego AI‑driven biotech, said it is preparing for an initial public offering after securing several large‑scale partnerships with major pharmaceutical companies. In its…
- Lexeo Therapeutics acquires Mantle Therapeutics for $8.3M to expand Friedreich ataxia pipelineLexeo Therapeutics announced it will acquire Mantle Therapeutics for an upfront payment of $8.3 million, aiming to broaden its Friedreich ataxia pipeline. The transaction could rise to $21.3 milli…